PRODUCT INFORMATION

SACLAC

Item No. 9003926

CAS Registry No.:	2248703-42-4
Formal Name:	2-chloro-N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-acetamide
MF:	$C_{20}H_{40}ClNO_3$
FW:	378.0
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SACLAC is supplied as a solid. A stock solution may be made by dissolving the SACLAC in the solvent of choice, which should be purged with an inert gas. SACLAC is soluble in chloroform.

Description

SACLAC is an irreversible inhibitor of acid ceramidase (K_i = 97.1 nM) and a derivative of the acid ceramidase inhibitor SABRAC (Item No. 9003925).[1] It decreases levels of sphingosine-1-phosphate (S1P) and increases total ceramide levels in OCI-AML-2 acute myeloid leukemia (AML) cells when used at a concentration of 2.5 µM.[2] SACLAC (10 and 20 µM) induces apoptosis in primary AML cells. It reduces leukemic burden in MV4-11 and U937 AML mouse xenograft models when administered at a dose of 5 mg/kg.

References

1. Ordóñez, Y.F., Abad, J.L., Aseeri, M., *et al.* Activity-based imaging of acid ceramidase in living cells. *J. Am. Chem. Soc.* **141(19)**, 7736-7742 (2019).
2. Pearson, J.M., Tan, S.-F., Sharma, A., *et al.* Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia. *Mol. Cancer Res.* **18(3)**, 352-363 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM